-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:我們將12個月目標價從129美元下調至124美元,基於2026年EBITDA預期,EV/EBITDA為9.8倍,略高於其三年平均水準8.9倍。我們將2026年每股收益預期上調0.02美元至8.21美元,並將2027年每股收益預期上調0.16美元至9.15美元。亞太地區表現突出,銷量較去年同期成長17%,帶動該業務板塊營收成長10%。北美食品罐頭銷量年增3%,其中寵物食品目前維持穩定成長,佔40%-45%。就疲軟態勢而言,美洲飲料業務銷售額成長16%,主要受成本上漲影響;但由於巴西銷售下降以及無法將原物料成本上漲轉嫁給消費者,營收年減10%。運輸包裝業務的利潤率在第一季也受到投入成本上漲的擠壓,但管理層預計這一趨勢將在2026年下半年逆轉。在印度的投資可望成為未來強勁的成長動力,預計印度市場規模將達到40億至50億件,年增15%至20%,而CCK將新增22億件的產能。
Related Articles
Argus Adjusts Price Target on Nasdaq to $103 From $98
Nasdaq (NDAQ) has an average rating of buy and mean price target of $110.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $91.54, Change: $-0.37, Percent Change: -0.40%
Argus Adjusts Price Target on IDEX to $250 From $240
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $214.86, Change: $-2.99, Percent Change: -1.37%
Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $470.05, Change: $-8.91, Percent Change: -1.86%